Taysha Gene Therapies Free Cash Flow 2020-2023 | TSHA
Taysha Gene Therapies free cash flow from 2020 to 2023. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Taysha Gene Therapies Annual Free Cash Flow |
| 2023 |
-76.89 |
| 2022 |
-109.01 |
| 2021 |
-132.35 |
| 2020 |
-30.81 |
| 2019 |
|
| Taysha Gene Therapies Quarterly Free Cash Flow |
| 2023-12-31 |
-76.89 |
| 2023-09-30 |
-60.75 |
| 2023-06-30 |
-42.80 |
| 2023-03-31 |
-24.09 |
| 2022-12-31 |
-109.01 |
| 2022-09-30 |
-121.41 |
| 2022-06-30 |
-90.58 |
| 2022-03-31 |
-49.37 |
| 2021-12-31 |
-132.35 |
| 2021-09-30 |
-83.82 |
| 2021-06-30 |
-48.38 |
| 2021-03-31 |
-22.57 |
| 2020-12-31 |
-30.81 |
| 2020-09-30 |
-10.91 |
| 2020-06-30 |
-4.17 |
| 2020-03-31 |
-1.70 |
| 2019-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.447B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
